Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Impact of prior lines of therapy before ASCT and CAR-T on aggressive NHL

Yi Lin • 4 Dec 2020
ASH 2020
Lymphoma Non-Hodgkin Lymphoma CAR-T

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, talks on the impact of prior lines of therapy before autologous stem cell transplant (ASCT) and CAR-T infusion on the outcomes of aggressive non-Hodgkin’s lymphoma (NHL). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Consultant: Kite/Gilead, Celgene/BMS, JUNO/BMS, BlueBird Bio, Janssen, Legend BioTech, Gamida Cells, Novartis, Iovance, Takeda, Fosun Kite
Grant/Research Support: Kite/Gilead, Celgene, BlueBird Bio, Janssen, Legend Biotech, Merck, Takeda, Boston Scientific
Data safety monitoring board: Sorrento
All funds paid to Mayo Clinic, no personal compensation.

More from Yi Lin

1:59
Factors to consider when choosing between cilta-cel and ide-cel for R/R multiple myeloma
Yi Lin • 9 Dec 2023
1:50
Real-world outcomes of teclistamab treatment in R/R multiple myeloma
Yi Lin • 9 Dec 2023
1:32
AEs associated with CAR-T in patients with triple-class exposed R/R MM: analysis from KarMMa-3
Yi Lin • 9 Dec 2023
3:04
Outpatient monitoring following CAR-T and BsAb treatment for patients with lymphoma and MM
Yi Lin • 9 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals